Coya Therapeutics (COYA) Current Deferred Revenue (2023 - 2025)
Coya Therapeutics (COYA) has disclosed Current Deferred Revenue for 3 consecutive years, with $1.2 million as the latest value for Q4 2025.
- Quarterly Current Deferred Revenue rose 41.21% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 41.21% year-over-year, with the annual reading at $1.2 million for FY2025, 41.21% up from the prior year.
- Current Deferred Revenue hit $1.2 million in Q4 2025 for Coya Therapeutics, up from $916712.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.2 million in Q4 2025 to a low of $573089.0 in Q3 2024.
- Historically, Current Deferred Revenue has averaged $851138.3 across 3 years, with a median of $848286.0 in 2024.
- Biggest YoY gain for Current Deferred Revenue was 59.96% in 2025; the steepest drop was 22.15% in 2025.
- Year by year, Current Deferred Revenue stood at $923109.0 in 2023, then decreased by 8.11% to $848286.0 in 2024, then soared by 41.21% to $1.2 million in 2025.
- Business Quant data shows Current Deferred Revenue for COYA at $1.2 million in Q4 2025, $916712.0 in Q3 2025, and $731075.0 in Q2 2025.